Iterum Therapeutics plc ITRMF

ITRMF Company Overview

Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel anti-infective therapies to address drug-resistant bacterial pathogens. The company operates within the biopharmaceutical and anti-infectives industries, with a primary emphasis on treatments for serious and life-threatening infections where resistance to existing antibiotics presents significant clinical challenges.

The company’s core asset is sulopenem, a next-generation beta-lactam antibiotic being developed in both oral and intravenous formulations. Iterum’s strategy centers on targeting multidrug-resistant gram-negative bacteria, particularly in urinary tract infections. Iterum Therapeutics plc was founded in 2015 through the combination of Iterum Therapeutics International Limited and the infectious disease business of Pfizer Inc., acquiring rights to sulopenem and related intellectual property. The company is incorporated in Ireland and is publicly traded on the Nasdaq under the ticker ITRM.